Recent advances in the research of 2,3-diaryl-1,3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors

Current Medicinal Chemistry

Volumn 19, Issue 13, 2012, Pages 2026-2037

  Tian, Ye ^a   Zhan, Peng ^a   Rai, Diwakar ^a   Zhang, Jiyan ^a   De Clercq, Erik ^b   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

1,3 Thiazolidin 4 ones; AIDS; Antiviral; Drug design; HIV; HIV 1 NNRTIs

Indexed keywords

2,3 DIARYL 1,3 THIAZOLIDIN 4 ONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

DRUG DISCOVERY; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINES;

EID: 84860527224     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800167383     Document Type: Article

References (56)

1. Turner, B.G.; Summers, M.F., Structural biology of HIV. J. Mol. Biol., 1999, 285, (1), 1-32. (Pubitemid 29034021)
2. Jonckheere, H.; Anné, J.; De Clercq, E., The HIV-1 reverse transcription (RT) process as target for RT Inhibitors. Med. Res. Rev., 2000, 20, (2), 129-154. (Pubitemid 30134322)
3. Hajos, G.; Riedl, Z.; Molnar, J.; Szabo, D., Nonnucleoside reverse transcriptase inhibitors. Drugs of the Future, 2000, 25, (2), 47-62. (Pubitemid 30120988)
4. Schaefer, W.; Friebe, W.G.; Leinert, H.; Mertens, A.; Poll, T.; Von der Saal, W.; Zilch, H.; Nuber, B.; Ziegler, M.L., Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and x-ray structure investigations. J. Med. Chem., 1993, 36, (6), 726-732. (Pubitemid 23105726)
5. Tavel, J.A.; Miller, K.D.; Masur, H., Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin. Infect. Dis., 1999, 28, (3), 643-676. (Pubitemid 29242549)
6. De Corte, B.L., From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4) benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem., 2005, 48, (6), 1689-1696. (Pubitemid 40396298)
7. Seminari, E.; Castagna, A.; Lazzarin, A., Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther, 2008, 6, (4), 427-433.
8. U.S. Food and Drug Administration. FDA Approves New HIV Treatment. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256087.htm (Accessed May 20, 2011).
9. Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Zappalà, M., Anti-HIV agents. I: synthesis and in vitro anti-HIV evaluation of novel 1H,3Hthiazolo[ 3,4-a]benzimidazoles. Farmaco, 1991, 46, (6), 817-823.
10. Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Zappalà, M., Anti-HIV agents II. synthesis and in vitro anti-HIV activity of novel 1H,3Hthiazolo[ 3,4-a]benzimidazoles. Farmaco, 1991, 46, (7-8), 925-933.
11. Chimirri, A.; Grasso, S.; Molica, C.; Monforte, A.M.; Monforte, P.; Zappalà, M.; Bruno, G.; Nicolò, F.; Witvrouw, M.; Jonckeere, H.; Balzarini, J.; De Clercq, E., Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2',6'-difluorophenyl) -1H,3H-thiazolo[3,4-a]benzimidiazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antivir.Chem.Chemother, 1997, 8, 363-370. (Pubitemid 27292638)
12. McMartin, C.; Bohacek, R.S., QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput. Aided Mol. Des., 1997, 11, (4), 333-344. (Pubitemid 127506740)
13. Barreca, M.L.; Carotti, A.; Carrieri, A.; Chimirri, A.; Monforte, A.M.; Pellegrini Calace, M.; Rao, A., Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg. Med. Chem., 1999, 7, (11), 2283-2292. (Pubitemid 30122730)
14. Barreca, M.L.; Chimirri, A.; De Luca, L.; Monforte, A.-M.; Monforte, P.; Rao, A.; Zappalà, M.; Balzarini, J.; De Clercq, E.; Pannecouque, C.; Witvrouw, M., Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg. Med. Chem. Lett., 2001, 11, (13), 1793-1796. (Pubitemid 32568322)
15. Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappalà, M.; Bruno, G.; Nicolo, F.; Scopelliti, R., Anti-HIV agents. V. Synthesis, structure and in vitro anti-HIV activity of novel 1H,3H-naphtho[2 ′,3 ′: 4,5]imidazo[1,2-c]thiazoles. Farmaco, 1997, 52, (11), 673-677. (Pubitemid 28167892)
16. Roth, T.; Morningstar, M.L.; Boyer, P.L.; Hughes, S.H.; Buckheit, R.W.; Michejda, C.J., Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. J. Med. Chem., 1997, 40, (26), 4199-4207. (Pubitemid 28042301)
17. Chimirri, A.; Grasso, S.; Monforte, A.M.; Monforte, P.; Rao, A.; Zappalà, M.; Bruno, G.; Nicolo, F.; Pannecouque, C.; Witvrouw, M.; De Clercq, E., Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles. Antivir. Chem. Chemother., 1998, 9, (5), 431-438. (Pubitemid 28446025)
18. Chimirri, A.; Grasso, S.; Monforte, P.; Rao, A.; Zappalà, M.; Monforte, A.M.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; De Clercq, E., Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a] benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir. Chem. Chemother., 1999, 10, (4), 211-217. (Pubitemid 29378079)
19. Chimirri, A.; Monforte, A.M.; Monforte, P.; Nicolo, F.; Rao, A.; Zappalà, M., Synthesis and structural features of new cyclofunctionalized benzimidazoles. Heterocycles, 2000, 53, (3), 613-620.
20. Chimirri, A.; Monforte, P.; Rao, A.; Zappalà, M.; Monforte, A.M.; De Sarro, G.; Pannecouque, C.; Witvrouw, M.; Balzarini, J.; De Clercq, E., Synthesis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles: non-nucleoside HIV-1 reverse transcriptase inhibitors. Antivir Chem Chemother, 2001, 12, (3), 169-174. (Pubitemid 32963916)
21. Rao, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappalà, M., Synthesis and anti-HIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Il Farmaco, 2002, 57, (10), 819-823. (Pubitemid 35440977)
22. Barreca, M.L.; Rao, A.; De Luca, L.; Zappalà, M.; Monforte, A.M.; Maga, G.; Pannecouque, C.; Balzarini, J.; De Clercq, E.; Chimirri, A.; Monforte, P., Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem., 2005, 48, (9), 3433-3437. (Pubitemid 40628061)
23. Barreca, M.L.; Chimirri, A.; De Clercq, E.; De Luca, L.; Monforte, A.-M.; Monforte, P.; Rao, A.; Zappalà, M., Anti-HIV agents: design and discovery of new potent RT inhibitors. Il Farmaco, 2003, 58, (3), 259-263. (Pubitemid 36279699)
24. Barreca, M.L.; Balzarini, J.; Chimirri, A.; De Clercq, E.; De Luca, L.; Holtje, H.D.; Holtje, M.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Rao, A.; Zappalà, M., Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J. Med. Chem., 2002, 45, (24), 5410-5413. (Pubitemid 35429180)
25. Rawal, R.K.; Tripathi, R.K.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin- 4-ones as anti-HIV agents. Medicinal Chemistry, 2007, 3, (4), 355-363. (Pubitemid 47082999)
26. Rao, A.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappalà, M., Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Il Farmaco, 2003, 58, (2), 115-120. (Pubitemid 36197647)
27. Murugesan, V.; Tiwari, V.S.; Saxena, R.; Tripathi, R.; Paranjape, R.; Kulkarni, S.; Makwana, N.; Suryawanshi, R.; Katti, S.B., Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem., 2011, 19, (22), 6919-6926.
28. Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappalà, M., 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Res., 2004, 63, (2), 79-84. (Pubitemid 39061772)
29. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin- 4-one analogs as anti-HIV-1 agents. Bioorg. Med. Chem., 2007, 15, (9), 3134-3142. (Pubitemid 46484339)
30. Prabhakar, Y.S.; Solomon, V.R.; Rawal, R.K.; Gupta, M.K.; Katti, S.B., CPMLR/ PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Qsar & Combinatorial Science, 2004, 23, (4), 234-244. (Pubitemid 39490415)
31. Prabhakar, Y.S.; Rawal, R.K.; Gupta, M.K.; Solomon, V.R.; Katti, S.B., Topological descriptors in modeling the HIV inhibitory activity of 2-aryl-3-pyridyl-thiazolidin-4-ones. Combinatorial Chemistry & High Throughput Screening, 2005, 8, (5), 431-437. (Pubitemid 41008790)
32. Roy, K.; Leonard, J.T., Classical QSAR modeling of anti-HIV 2,3-diaryl-1,3-thiazolidin-4-ones. Qsar & Combinatorial Science, 2005, 24, (5), 579-592. (Pubitemid 41074326)
33. Chen, H.; Bai, J.; Jiao, L.L.; Guo, Z.H.; Yin, Q.M.; Li, X.L., Design, microwave-assisted synthesis and HIV-RT inhibitory activity of 2-(2,6-dihalophenyl)-3-(4,6-dimethyl-5-(un)substituted-pyrimidin-2-yl) thiazolidin-4-ones. Bioorg. Med. Chem., 2009, 17, (11), 3980-3986.
34. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,13-thiazolidin-4-ones as anti-HIV agents. Bioorg. Med. Chem., 2007, 15, (4), 1725-1731. (Pubitemid 46394053)
35. Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E., 2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. Bioorg. Med. Chem., 2005, 13, (24), 6771-6776. (Pubitemid 41571222)
36. Rawal, R.K.; Tripathi, R.; Kulkarni, S.; Paranjape, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., 2-(2,6-dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1, 3-thiazolidin-4-ones: anti-HIV agents. Chemical Biology & Drug Design, 2008, 72, (2), 147-154.
37. Rawal, R.K.; Solomon, V.R.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E., Synthesis and QSAR studies on thiazolidinones as anti-HIV agents. Combinatorial Chemistry & High Throughput Screening, 2005, 8, (5), 439-443. (Pubitemid 41008791)
38. Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappalà, M., Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Il Farmaco, 2004, 59, (1), 33-39. (Pubitemid 38134282)
39. Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B., Molecular surface features in modeling the HIV-1 RT inhibitory activity of 2-(2,6-disubstituted phenyl)-3-(substituted pyrimidin-2-yl)-thiazolidin-4-ones. Qsar & Combinatorial Science, 2007, 26, (3), 398-406. (Pubitemid 46932866)
40. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E., Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4- ones as anti-HIV agents. European Journal of Medicinal Chemistry, 2008, 43, (12), 2800-2806.
41. Rao, A.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Zappalà, M., Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Il Farmaco, 2002, 57, (9), 747-751. (Pubitemid 35287009)
42. Lamoureux, G.; Artavia, G., Use of the adamantane structure in medicinal chemistry. Curr. Med. Chem., 2010, 17, (26), 2967-2978.
43. Balzarini, J.; Orzeszko, B.; Maurin, J.K.; Orzeszko, A., Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones. European Journal of Medicinal Chemistry, 2007, 42, (7), 993-1003. (Pubitemid 46907342)
44. Balzarini, J.; Orzeszko-Krzesinska, B.; Maurin, J.K.; Orzeszko, A., Synthesis and anti-HIV studies of 2-and 3-adamantyl-substituted thiazolidin-4-ones. European Journal of Medicinal Chemistry, 2009, 44, (1), 303-311.
45. Pitta, E.; Crespan, E.; Geronikaki, A.; Maga, G.; Samuele, A., Novel thiazolidinone derivatives with an uncommon mechanism of inhibition towards HIV-1 reverse transcriptase. Letters in Drug Design & Discovery, 2010, 7, (4), 228-234.
46. Patani, G.A.; LaVoie, E.J., Bioisosterism: a rational approach in drug design. Chem. Rev., 1996, 96, (8), 3147-3176. (Pubitemid 126641132)
47. Brown, N.; Jacoby, E., On scaffolds and hopping in medicinal chemistry. Mini-Reviews in Medicinal Chemistry, 2006, 6, (11), 1217-1229. (Pubitemid 44697101)
48. Kroeger Smith, M.B.; Hose, B.M.; Hawkins, A.; Lipchock, J.; Farnsworth, D.W.; Rizzo, R.C.; Tirado-Rives, J.; Arnold, E.; Zhang, W.; Hughes, S.H.; Jorgensen, W.L.; Michejda, C.J.; Smith, R.H., Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-arylsubstituted benzimidazole analogs. J. Med. Chem., 2003, 46, (10), 1940-1947. (Pubitemid 36532236)
49. Morningstar, M.L.; Roth, T.; Farnsworth, D.W.; Kroeger Smith, M.; Watson, K.; Buckheit, R.W.; Das, K.; Zhang, W.; Arnold, E.; Julias, J.G.; Hughes, S.H.; Michejda, C.J., Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J. Med. Chem., 2007, 50, (17), 4003-4015. (Pubitemid 47301733)
50. Das, K.; Lewi, P.J.; Hughes, S.H.; Arnold, E., Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol., 2005, 88, (2), 209-231. (Pubitemid 39579659)
51. Das, K.; Clark, A.D.; Lewi, P.J.; Heeres, J.; de Jonge, M.R.; Koymans, L.M.H.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; De Corte, B.; Kavash, R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pauwels, R.; de Béthune, M.-P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.J.; Arnold, E., Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem., 2004, 47, (10), 2550-2560. (Pubitemid 38580092)
52. Pauwels, R., Aspects of successful drug discovery and development. Antiviral Res., 2006, 71, (2-3), 77-89. (Pubitemid 44223771)
53. Zhan, P.; Liu, X.; Li, Z.; Pannecouque, C.; De Clercq, E., Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem., 2009, 16, (29), 3903-3917.
54. Zhan, P.; Chen, X.; Li, D.; Fang, Z.; De Clercq, E.; Liu, X., HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med. Res. Rev., 2011 doi: 10.1002/med.20241.
55. Huang, F.; Koenen-Bergmann, M.; Macgregor, T.R.; Ring, A.; Hattox, S.; Robinson, P., Pharmacokinetic and safety evaluation of BILR 355, a secondgeneration nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother., 2008, 52, (12), 4300-4307.
56. Viegas-Junior, C.; Danuello, A.; Bolzani, V.D.; Barreir, E.J.; Fraga, C.A.M., Molecular hybridization: a useful tool in the design of new drug prototypes. Curr. Med. Chem., 2007, 14, (17), 1829-1852. (Pubitemid 47163402)